Navigation Links
Repligen Receives Research Grants to Support Friedreich's Ataxia Development Program
Date:9/4/2008

REF="http://www.repligen.com" target="_new">http://www.repligen.com.

This press release contains forward-looking statements which are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The forward-looking statements in this release do not constitute guarantees of future performance. Investors are cautioned that statements in this press release which are not strictly historical statements, including, without limitation, statements regarding current or future financial performance and position, management's strategy, plans and objectives for future operations, plans and objectives for product development, plans and objectives for present and future clinical trials and results of such trials, plans and objectives for regulatory approval, litigation, intellectual property, product development, manufacturing plans and performance such as the anticipated growth in the monoclonal antibody market and our other target markets and projected growth in product sales, constitute forward-looking statements. Such forward-looking statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated, including, without limitation, risks associated with: the success of current and future collaborative relationships, the market acceptance of our products, our ability to compete with larger, better financed pharmaceutical and biotechnology companies, new approaches to the treatment of our targeted diseases, our expectation of incurring continued losses, our uncertainty of product revenues and profits, our ability to generate future revenues, our ability to raise additional capital to continue our drug development programs, the success of our clinical trials, our ability to develop and commercialize products, our ability to obtain required regulatory approvals, our compliance with all Food an
'/>"/>

SOURCE Repligen Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Repligen Announces Conference Call of Third Quarter Fiscal Year 2008 Results
2. Repligen Announces Settlement with Bristol-Myers Squibb in Orencia(R) Lawsuit
3. Repligen Reports Fourth Quarter and Fiscal Year 2008 Financial Results
4. Repligen Announces Conference Call of First Quarter Fiscal Year 2009 Results
5. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
6. Ciphergen Biosystems Receives Noncompliance Letter From The Nasdaq Stock Market
7. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
8. Anesiva Receives FDA Approval for Zingo(TM), a New, Innovative Product to Reduce Pain Associated with Needle Insertion Procedures in Children
9. IsoTis Receives FDA Clearance for Accell Family of Products
10. Actavis Receives Approval of Fentanyl Transdermal System in the U.S.
11. AGA Medical Corporation Receives FDA and CE Mark Approvals for the AMPLATZER Vascular Plug II
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... Mass. (PRWEB) July 10, 2014 Terascala, ... today announced that Alan Swahn, a former vice president ... executive team as vice president of marketing. Terascala’s software ... Dell and NetApp create the highest performance and most ... been appointed to guide Terascala’s channel expansion and broaden ...
(Date:7/10/2014)... Senior supply chain management executives from ... the challenges of “Reducing Cost, Lead Time, & Defects ... sourcing. Describing the partnership of the Bio Supply Management ... Institute ( SCMI) of the University of San ... the Kroc Institute of Peace and Justice in San ...
(Date:7/10/2014)... -- Research and Markets ( http://www.researchandmarkets.com/research/s3bqj2/photonic ) has ... Integrated Circuit (Monolithic Integration, Hybrid Integration, Module Integration) ... their offering. http://photos.prnewswire.com/prnh/20130307/600769 ... traces its roots in the latter half of ... went unexplored and unfulfilled for several decades owing ...
(Date:7/10/2014)... new study published today in the journal PNAS ... found that time of day and sleep deprivation have ... be crucial when looking at the best time of ... heart disease, and for administering medicines effectively. , Researchers ... Cancer Research, London, investigated the links between sleep deprivation, ...
Breaking Biology Technology:Terascala Expands Executive Team 2Terascala Expands Executive Team 3Biotech & Biopharm Supply Chain Management Executives Launch BSMA in San Diego 2Biotech & Biopharm Supply Chain Management Executives Launch BSMA in San Diego 3Biotech & Biopharm Supply Chain Management Executives Launch BSMA in San Diego 4International Photonic Integrated Circuit (Monolithic Integration, Hybrid Integration, Module Integration) Market - Forecasts to 2019 2Time of day crucial to accurately test for diseases, new research finds 2
... (Euronext: AMT), a leader in the field of,human gene ... for the full year 2008 on Tuesday, February 24, ... these results, the Company will,conduct a conference call that ... The dial-in number for the Netherlands is 0800-949-4166 ...
... 18 Transgenomic Inc. (OTC Bulletin Board: TBIO) announces the following Webcast: , , ... Conference Call, ... Eastern, Where: http://www.transgenomic.com/events.asp?id=6 , How: ... at the, ...
... Directors wishes to confirm to Stockholders that at its meeting ... 15 with effect from February 17, 2009. This initiative ... interests of keeping stockholders and other stakeholders informed the Board ... release the company from its United States Securities and Exchange ...
Cached Biology Technology:AMT to Release Full Year 2008 Results on February 24, 2009 2Webcast Alert: Transgenomic Inc. Announces Fourth Quarter 2008 Earnings Release Conference Call Webcast 2EESTECH Inc - Release From SEC Filing 2EESTECH Inc - Release From SEC Filing 3EESTECH Inc - Release From SEC Filing 4
(Date:7/11/2014)... Canyon fire started near the City of Entiat on ... resources, the fire quickly grew to over 1,000 acres ... the fire is under investigation by the Washington Department ... with existing local resources in developing fire control strategies ... (USFS), Washington State Department of Natural Resources, (WA DNR), ...
(Date:7/11/2014)... Stem Cell scientists have set a "mouse TRAP" to ... by a recent study published in the Journal ... uses a technique called TRAP to extract cellular and ... Invented by scientists at the Rockefeller Institute for Medical ... to the protein-making machinery, or ribosomes, of the cell ...
(Date:7/11/2014)... develop relationships with other group members to reduce aggression ... baboons the strategy for grooming activities shows a certain ... in the scientific journal Biology Letters . , ... not practiced without ulterior motives. To be groomed has ... while grooming another individual can provide access to infants, ...
Breaking Biology News(10 mins):Baboons groom early in the day to get benefits later 2
... completely, the end products are carbon dioxide and water. Today ... into the air adding to global warming; or the ... unknown consequences. But it,s not impossible, says Liviu M. ... St. Louis, to drive things the other way, turning carbon ...
... Washington, D.C. (November 30, 2010) -- A broad review of ... the Journal of Renewable and Sustainable Energy . The ... viable power source but that the current fuel cycle is ... of future costs must be built on basic assumptions that ...
... DURHAM, N.C. As the U.S. Environmental Protection Agency ... a Duke University study identifies new monitoring protocols and ... predict the ecological impacts of coal ash contaminants. ... and where we look for coal ash contaminants," says ...
Cached Biology News:Chemistry for greenhouse gases 2Chemistry for greenhouse gases 3Chemistry for greenhouse gases 4Duke scientists look deeper for coal ash hazards 2
BD Biocoat Matrigel Matrix Thin Layer 35 mm Culture Dishes...
... cultured in RPMI 1640 with 2 mM L-glutamine ... In order to keep the antigens in ... The cells are arrayed on a 12-well ... surface specifically treated to enhance cellular attachment and ...
... are derived from the Spodoptera frugiperda Sf21 cell ... in transfections, plaque assays, virus production, and protein ... that optimizes recovery of viable cells after thawing. ... Insect Cell Medium and can also be grown ...
... is a software package that provides ... for custom buffer creation, set-up of ... crystallization trials. The software helps crystallographers ... automated protein crystallography: ...
Biology Products: